Experimental design and characterization of dual-antibody-conjugated all-trans retinoic acid-loaded lipid nanoparticles as a potential cancer therapy
| dc.authorid | 0000-0002-4634-3864 | |
| dc.contributor.author | İşlek, Zeynep | |
| dc.contributor.author | Sağıroğlu, Ali Asram | |
| dc.contributor.author | Üçışık, Mehmet Hikmet | |
| dc.contributor.author | Kırbaş, Oğuz Kaan | |
| dc.contributor.author | Demirel, Erhan | |
| dc.contributor.author | Yurdasiper, Aysu | |
| dc.contributor.author | Şahin, Fikrettin | |
| dc.contributor.author | Özer, Özgen | |
| dc.date.accessioned | 2024-09-20T11:42:02Z | |
| dc.date.available | 2024-09-20T11:42:02Z | |
| dc.date.issued | 2024 | |
| dc.department | İstanbul Medipol Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümü | |
| dc.description.abstract | Antibody-targeted immunotherapy has emerged in cancer therapies regarding checkpoint inhibition with monoclonal antibodies, such as anti-programmed death-ligand 1 (anti-PD-L1) either given alone or in combination. However, when given alone, it may fail to activate tumor-specific T cells. The combinational therapy of anti-PD-L1 with anti-4-1BB and all-trans retinoic acid (ATRA) has come into prominence due to disease heterogeneity, resulting in the synergistic effects associated with greater T-cell responses. This study introduces anti-PD-L1 and anti-4-1BB-conjugated ATRA-loaded solid lipid nanoparticles (SLNs), where the Design-Expert Program was applied for the optimization. Accordingly, antibody–conjugated ATRA-loaded SLNs had uniform dispersions with mean diameters of 179.6 ± 12.6 nm. The formulations achieved the encapsulation efficiency (EE %) of ATRA at 21.2 ± 1.4 %, regarding the three-dimensional response surface graph. The binding efficiency of anti-4-1BB and anti-PD-L1 antibodies were determined as 85.59 ± 7.3 % and 90.02 ± 5.4 %, respectively. The release profile of formulations indicated the biphasic release of ATRA (ie., 76 ± 4.4 %) from SLNs within 24 h via the Higuchi model. Particle size distributions of SLNs displayed a 7 % increase (i.e., 190.5 ± 7.63 nm) at 4 °C over 2 months. The experimental design of anti-PD-L1- and anti-4-1BB-conjugated- ATRA-loaded SLNs highlighted the promising strategy for the development of alternative formulations and the potential approach for further cancer therapies. | |
| dc.description.sponsorship | Yeditepe University, Turkiye | en_US |
| dc.identifier.citation | İşlek, Z., Sağıroğlu, A. A., Üçışık, M. H., Kırbaş, O. K., Demirel, E., Yurdasiper, A. ... Özer, Ö. (2024). Experimental design and characterization of dual-antibody-conjugated all-trans retinoic acid-loaded lipid nanoparticles as a potential cancer therapy. Journal of Drug Delivery Science and Technology, 100. http://dx.doi.org/10.1016/j.jddst.2024.105995 | |
| dc.identifier.doi | 10.1016/j.jddst.2024.105995 | |
| dc.identifier.issn | 1773-2247 | |
| dc.identifier.issn | 2588-8943 | |
| dc.identifier.scopus | 2-s2.0-85200490102 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | http://dx.doi.org/10.1016/j.jddst.2024.105995 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/12819 | |
| dc.identifier.volume | 100 | |
| dc.identifier.wos | 001290634700001 | en_US |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.institutionauthor | Demirel, Erhan | |
| dc.language.iso | en | |
| dc.relation.ispartof | Journal of Drug Delivery Science and Technology | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | All-Trans Retinoic Acid (ATRA) | |
| dc.subject | Anti-4-1BB | |
| dc.subject | Anti-Programmed Death-Ligand 1 (Anti-PD-L1) | |
| dc.subject | Antibody Conjugation | |
| dc.subject | Solid Lipid Nanoparticles (Slns) | |
| dc.subject | Surface Modification | |
| dc.title | Experimental design and characterization of dual-antibody-conjugated all-trans retinoic acid-loaded lipid nanoparticles as a potential cancer therapy | |
| dc.type | Article |
